Post-hoc analysis of 12,637 patients shows liraglutide and semaglutide reduce cardiovascular events and kidney disease in type 2 diabetes patients regardless of baseline blood pressure.
12,637 patientsCombined LEADER and SUSTAIN 6 analysis showing consistent cardiorenal benefits across all BP categories
What the researchers found
No statistical heterogeneity in cardiovascular (MACE) or nephropathy outcomes across blood pressure categories for either liraglutide or semaglutide vs placebo.
Why it matters
Clinicians can prescribe GLP-1 drugs for cardiovascular and kidney protection in type 2 diabetes without worrying that high or low blood pressure will negate the benefits.
The numbers in context
LEADER: 9,340 patients; SUSTAIN 6: 3,297; 70-74% hypertensive; no heterogeneity for MACE or nephropathy across BP categories
How the study worked
Post-hoc analysis of two randomized controlled trials (LEADER and SUSTAIN 6) using Cox proportional hazards models adjusted for cardiorenal risk factors, stratified by baseline BP category.
Who was studied
Type 2 diabetes patients at high cardiovascular risk (human)
What this study cannot tell us
Post-hoc analysis (not pre-specified); BP measured at baseline only (not longitudinally); separate trial analyses (not pooled); may lack power for some subgroups.
How to read the evidence
Strong — large-scale post-hoc analysis of two major randomized controlled trials with robust statistical methodology.
When this study was published
Published in 2020; semaglutide cardiovascular evidence has strengthened further with SELECT trial results (2023).
The bigger picture
GLP-1 receptor agonists are increasingly recognized as cardiovascular protective drugs beyond their glucose-lowering effects. This analysis removes blood pressure as a concern when prescribing them.
Questions still open
- Do GLP-1 agonists actually lower blood pressure as part of their cardioprotective mechanism?
- Would these results hold in patients with resistant hypertension?
- Is there a combined benefit of GLP-1 agonists plus intensive BP control?
Common questions
Should I avoid semaglutide if I have high blood pressure?
What is MACE?
Read the original research
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Diabetes, obesity & metabolism, 22(9), 1690-1695
Citation
Leiter, Lawrence A; Bain, Stephen C; Bhatt, Deepak L; Buse, John B; Mazer, C David; Pratley, Richard E; Rasmussen, Søren; Ripa, Maria Sejersten; Vrazic, Hrvoje; Verma, Subodh. (2020). The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.. Diabetes, obesity & metabolism, 22(9), 1690-1695. https://doi.org/10.1111/dom.14079